Sugi Predict

Sugi Predict / Compounds / SCHEMBL19103283

SCHEMBL19103283

SCHEMBL19103283

Cn1c(C#N)c(-c2ccnc(Cl)n2)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.41
▸ CYP11B2 P19099 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ GPR3 P46089 1/20 0.34
▸ RPS6KA5 O75582 1/20 0.34
▸ MAPK14 Q16539 1/20 0.33
▸ IMPDH2 P12268 1/20 0.33
▸ TEK Q02763 1/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ PTK2 Q05397 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ MAPK9 P45984 1/20 0.32
▸ MAPK10 P53779 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ TSHR P16473 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17822333 0.81 ALDH1A1 (0.39) SMN1; SMN2RECQLMEN1KMT2AGPR3
SCHEMBL30337202 0.81 ALDH1A1 (0.39) SMN1; SMN2RECQLMEN1KMT2AGPR3
SCHEMBL17384806 0.78 TEK (0.46) EGFRCYP11B2SMN1; SMN2KMT2AMAPK14
SCHEMBL30337199 0.78 TEK (0.46) EGFRCYP11B2SMN1; SMN2KMT2AMAPK14
SCHEMBL19103280 0.73 KDM4E (0.47) EGFRSRCKMT2APOLBALDH1A1
SCHEMBL21165735 0.73 KMT2A (0.40) EGFRCYP11B2KMT2ATEKGAA
SCHEMBL31105657 0.73 KDM4E (0.47) EGFRSRCKMT2APOLBALDH1A1
SCHEMBL17384819 0.72 EGFR (0.48) EGFRCYP11B2MAPK14TEKAKT1
SCHEMBL5096322 0.69 MKNK1 (0.50) EGFRSMN1; SMN2IMPDH2ALDH1A1TSHR
SCHEMBL29419125 0.69 MKNK1 (0.50) EGFRSMN1; SMN2IMPDH2ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190218212-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ARIAD PHARMACEUTICALS, INC. 2019-07-18 — — US disclosed
US-10227342-B2 Heteroaryl compounds for kinase inhibition ARIAD PHARMACEUTICALS, INC. (US) 2019-03-12 — — US disclosed
US-9796712-B2 Heteroaryl compounds for kinase inhibition ARIAD PHARMACEUTICALS, INC. (US) 2017-10-24 — — US disclosed
US-9796712-B2 Heteroaryl compounds for kinase inhibition ARIAD PHARMACEUTICALS, INC. (US) 2017-10-24 — — US disclosed
US-20170253594-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-07 — — US disclosed
US-20170253594-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-07 — — US disclosed
US-20170197962-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ARIAD PHARMACEUTICALS, INC. 2017-07-13 — — US disclosed
US-20170197962-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ARIAD PHARMACEUTICALS, INC. 2017-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218212-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ERBB2, EGFR, ERBB3 EGFR 2/4885CYP11B2 3400/4885SRC 6/4885
US-20170197962-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ERBB2, EGFR, ERBB3 EGFR 2/4885CYP11B2 3400/4885SRC 6/4885
US-10227342-B2 Heteroaryl compounds for kinase inhibition ERBB2, EGFR, ERBB3 EGFR 2/4885CYP11B2 3400/4885SRC 6/4885
US-20170253594-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ERBB2, EGFR, ERBB3 EGFR 2/4885CYP11B2 3400/4885SRC 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.